Alliqua Signs Distribution Agreement for SilverSeal® and Hydress® Wound Dressings U.S. Health Care Services Company to Distribute SilverSeal and Hydress Dressings to Alternate Site Market in All 50 States
LANGHORNE, Pennsylvania, October 21, 2013 /PRNewswire/ --
Alliqua, Inc. (OTCQB: ALQA) ("Alliqua" or "the Company"), has signed a distribution agreement with McKesson Medical-Surgical, by which their U.S. distribution network will stock and offer for sale Alliqua's SilverSeal® and Hydress® wound dressings to healthcare customers nationwide.
David Johnson, Chief Executive Officer of Alliqua, said, "This encompasses expanding our distribution network within the U.S. for our SilverSeal® and Hydress® wound dressings. McKesson Medical-Surgical is one of the most well-known and respected health care distributors in the U.S. market. The expansion in distribution made possible by this agreement will assist customers with easy access to these products across the continuum of alternate site health care. "
Brad C. Barton, Chief Operating Officer of Alliqua, stated, "Signing an agreement with McKesson Medical-Surgical is very exciting to our customer base. Whether in home care, long term care or elsewhere in the alternate site market, customers can access our products from a source widely familiar to those in the position of purchasing health care supplies.
Alliqua's SilverSeal is a flexible, sterile hydrogel dressing that incorporates the antimicrobial properties of silver. It is designed for use on partial and full-thickness dermal ulcers, leg ulcers, superficial wounds, abrasions, first and second degree burns, donor sites and over debrided and grafted partial thickness wounds.
Alliqua's Hydress is a cross-linked polymer-based gel that is able to provide and maintain a moist wound environment. There are several benefits associated with increased moisture content, including the cleansing and autolytic debriding of necrotic tissue.
Other terms of the agreement were not disclosed.
McKesson Medical-Surgical's parent, McKesson Corporation, currently ranked 14th on the FORTUNE 500 list, is a healthcare services and information technology company dedicated to making the business of healthcare run better. McKesson Medical-Surgical works with payers, hospitals, physician offices, pharmacies, pharmaceutical companies and others across the spectrum of care to build healthier organizations that deliver better care to patients in every setting. McKesson Medical-Surgical helps its customers improve their financial, operational, and clinical performance with solutions that include pharmaceutical and medical-surgical supply management, healthcare information technology, and business and clinical services. For more information, visit http://www.mckesson.com.
About Alliqua, Inc.
Alliqua, Inc. (ALQA) ("Alliqua") is a biopharmaceutical company focused on the development, manufacturing, and distribution of proprietary transdermal wound care and drug delivery technologies. Alliqua's technology platform produces hydrogels, a 3-dimensional cross-linked network of water soluble polymers capable of numerous chemical configurations.
Alliqua currently markets its new line of 510(k) FDA-approved hydrogel products for wound care under the SilverSeal® brand, as well as the sorbion sachet S and sorbion sana wound care products. Alliqua's electron beam production process, located at its 16,000 square foot GMP manufacturing facility in Langhorne, PA, allows Alliqua to develop and custom manufacture a wide variety of hydrogels. Alliqua's hydrogels can be customized for various transdermal applications to address market opportunities in the treatment of wounds as well as the delivery of numerous drugs or other agents for pharmaceutical and cosmetic industries. Additionally, Alliqua's drug delivery platform, in combination with certain active pharmaceutical ingredients, can provide pharmaceutical companies with a transdermal technology to enhance patient compliance and potentially extend the patent life of valuable drug franchises.
Any statements contained in this press release regarding our ongoing research and development and the results attained by us to-date have not been evaluated by the Food and Drug Administration.
Legal Notice Regarding Forward-Looking Statements
This release contains forward-looking statements. Forward-looking statements are generally identifiable by the use of words like "may," "will," "should," "could," "expect," "anticipate," "estimate," "believe," "intend," or "project" or the negative of these words or other variations on these words or comparable terminology. The reader is cautioned not to put undue reliance on these forward-looking statements, as these statements are subject to numerous factors and uncertainties outside of the our control that can make such statements untrue, including, but not limited to, inadequate capital, adverse economic conditions, intense competition, lack of meaningful research results, entry of new competitors and products, adverse federal, state and local government regulation, termination of contracts or agreements, technological obsolescence of our products, technical problems with our research and products, price increases for supplies and components, inability to carry out research, development and commercialization plans, loss or retirement of key executives and research scientists and other specific risks. We currently have no commercial products intended to diagnose, treat, prevent or cure any disease. The statements contained in this press release regarding our ongoing research and development and the results attained by us to-date have not been evaluated by the Food and Drug Administration. There can be no assurance that further research and development, and/or whether clinical trial results, if any, will validate and support the results of our preliminary research and studies. Further, there can be no assurance that the necessary regulatory approvals will be obtained or that we will be able to develop new products on the basis of our technologies. In addition, other factors that could cause actual results to differ materially are discussed in our Annual Report on Form 10-K/A filed with the SEC on May 16, 2013, and our most recent Form 10-Q filings with the SEC. Investors and security holders are urged to read these documents free of charge on the SEC's web site at http://www.sec.gov. We undertake no obligation to publicly update or revise our forward-looking statements as a result of new information, future events or otherwise.
Contacts for Alliqua, Inc.
Brian M. Posner
Chief Financial Officer
Dian Griesel Int'l.
Dian Griesel Int'l.
Susan Forman or Laura Radocaj
SOURCE Alliqua, Inc.